Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16560286 | 1.00 | LMNA (0.48) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL30454596 | 1.00 | LMNA (0.48) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL14373886 | 1.00 | LMNA (0.48) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL17947385 | 0.84 | LMNA (0.45) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL20202580 | 0.84 | LMNA (0.45) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL8257922 | 0.84 | LMNA (0.45) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL31607076 | 0.83 | ADRB1 (0.47) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL23231419 | 0.82 | LMNA (0.44) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL18406260 | 0.82 | LMNA (0.44) | LMNAADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL8282358 | 0.82 | LMNA (0.44) | LMNAADRB1ADRA2AADRB3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-8278475-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2012-10-02 | — | — | US | disclosed |
| US-20120136167-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2012-05-31 | — | — | US | disclosed |
| US-8026396-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20110137056-A1 | Chemical Process For Preparation Of Intermediates | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7863469-B2 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-20100331575-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-7790927-B2 | Using hypochlorite in water in presence of alkali metal hydroxide | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20040077059-A1 | Process for the preparation of enantiomerically enriched esters and alcohols | DSM IP ASSETS B.V. (NL) | 2004-04-22 | — | — | US | disclosed |
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1283898-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ESTERS AND ALCOHOLS | DSM N.V. (NL) | 2003-02-19 | — | — | EP | disclosed |
| US-6410554-B1 | ADRENERGIC ANTAGONIST | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2001090396-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ESTERS AND ALCOHOLS | DSM N.V. (NL) | 2001-11-29 | — | — | WO | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | LMNA 1275/4885ADRB1 3392/4885ADRA2A 3689/4885 |
| US-20100331575-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | LMNA 3009/4885ADRB1 61/4885ADRA2A 72/4885 |
| US-20110137056-A1 | Chemical Process For Preparation Of Intermediates | DHPS, CYP3A5, CYP3A43 | LMNA 3158/4885ADRB1 1784/4885ADRA2A 1916/4885 |
| US-20120136167-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP2S1, CYP1B1 | LMNA 3051/4885ADRB1 71/4885ADRA2A 80/4885 |
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | TBXA2R, F2R, F2 | LMNA 2978/4885ADRB1 804/4885ADRA2A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.